Endocrine therapy in the treatment of metastatic breast cancer

被引：73

作者：

Buzdar, AU ^{[1
]}

机构：

[1] MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77037 USA

来源：

SEMINARS IN ONCOLOGY | 2001年 / 28卷 / 03期

关键词：

D O I：

10.1053/sonc.2001.23495

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：291 / 304

页数：14

共 94 条

[1]

[Anonymous], 1992, Lancet, V339, P1

[2]

[Anonymous], COMPUTER SCI EC MANA

[3] EFFECTS OF TAMOXIFEN TREATMENT ON PLASMA-LIPIDS AND LIPOPROTEIN LIPID-COMPOSITION [J].

BAGDADE, JD ;

WOLTER, J ;

SUBBAIAH, PV ;

RYAN, W .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (04) :1132-1135

[4] ENDOCRINOLOGIC AND CLINICAL-EVALUATION OF 2 DOSES OF FORMESTANE IN ADVANCED BREAST-CANCER [J].

BAJETTA, E ;

ZILEMBO, N ;

BUZZONI, R ;

NOBERASCO, C ;

DILEO, A ;

BARTOLI, C ;

MERSON, M ;

SACCHINI, V ;

MOGLIA, D ;

CELIO, L ;

NELLI, P .

BRITISH JOURNAL OF CANCER, 1994, 70 (01) :145-150

[5]

Beatson GT., 1896, LANCET, V148, P104, DOI DOI 10.1016/S0140-6736(01)72307-0

[6] Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study [J].

Boccardo, F ;

Amoroso, D ;

Iacobelli, S ;

Irtelli, L ;

Farris, A ;

Mustacchi, G ;

Mesiti, M ;

Brema, F ;

Pacini, P ;

Cortesi, E ;

Nardini, P ;

Guida, G ;

Langenaeken, C .

ANNALS OF ONCOLOGY, 1997, 8 (08) :745-750

[7]

Brunetti M, 1998, EUR CYTOKINE NETW, V9, P446

[8] TAMOXIFEN, SERUM-LIPOPROTEINS AND CARDIOVASCULAR RISK [J].

BRUNING, PF ;

BONFRER, JMG ;

HART, AAM ;

DEJONGBAKKER, M ;

LINDERS, D ;

VANLOON, J ;

NOOYEN, WJ .

BRITISH JOURNAL OF CANCER, 1988, 58 (04) :497-499

[9]

BUZDAR A, 2000, P AN M AM SOC CLIN, V19, pA154

[10]

Buzdar AU, 1996, CANCER, V77, P2503, DOI 10.1002/(SICI)1097-0142(19960615)77:12<2503::AID-CNCR13>3.0.CO

← 1 2 3 4 5 6 7 8 9 10 →